Stifel analyst Stephen Willey resumed coverage of Arcellx (ACLX) with a Buy rating and $129 price target The firm believes anito-cel is “poised to emerge” as a best-in-class BCMA-targeting CAR T therapy for multiple myeloma and anticipates a year-end 2025 BLA submission of iMMagine-1 data to serve as the basis of an approval and launch in the second half of 2026. From there, it expects early-FY27 iMMagine-3 mPFS data serving as the basis of label expansion into second-line and later patients, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACLX:
- Arcellx assumed with a Neutral at Cantor Fitzgerald
- Promising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Efficacy, Safety, and Financial Position
- Arcellx Inc’s Strong Positioning and Financial Stability Support Buy Rating Amid Anticipated FDA Approval
- 3 Stocks to Buy Now, According to the Technical Analysis